2 型糖尿病伴或不伴并发症患者的循环人抗核仁抗体 (ANCAb) 和生化参数。
Circulating human anti nucleolus antibody (ANCAb) and biochemical parameters in type 2 diabetic patients with and without complications.
机构信息
Medical Chemistry Department, College of Medicine, University of Duhok-Iraq, Duhok, Iraq.
Basic Sciences Unit, College of Nursing, University of Duhok-Iraq, Duhok, Iraq.
出版信息
PLoS One. 2020 Aug 17;15(8):e0237109. doi: 10.1371/journal.pone.0237109. eCollection 2020.
INTRODUCTION
There is no evidence on the role of Human Anti Nucleolus Antibody (ANCAb) in type 2 diabetes mellitus (T2DM). We compared prevalence and concentration of ANCAb between age and a gender-matched sample of T2DM with and without diabetes-related complications.
METHODS
In this study, the reaction to ANCAb was compared quantitatively between 38 T2DM patients complicated with microvascular conditions and 43 T2DM without complications as controls.
RESULTS
The patients in complicated and non-complicated groups were comparable in diabetes duration (9.0 vs. 5.0 years; P = 0.065), respectively. The study found that 27 cases (71.1%) of the complicated group reacted to ANCAb test compared to 25 (58.1%) in non-complicated patients (P = 0.226; 3.53 vs. 2.72 ng/mL; P = 0.413). The reaction response to ANCAb in patients with neuropathy and cardiovascular complications was 80.0%, 76.2% in patients with neuropathy compared to 58.1% in the control group (P = 0.398). The reaction response to ANCAb in patients with mono-complication was 72.7% compared 68.8% in patients with multi-complication (P = 0.466). Similarly, 76.2% of patients with T2DM and complicated with neuropathy (n = 21 patients) reacted to ANCAb compared to 58.1% in control patients with (P = 0.158).
CONCLUSIONS
Reaction to ANCAb was not statistically different between the T2DM patients with and without complications.
简介
目前尚无关于抗核仁抗体（ANCAb）在 2 型糖尿病（T2DM）中的作用的证据。我们比较了年龄相匹配的 T2DM 患者中伴有和不伴有糖尿病相关并发症的 ANCAb 的患病率和浓度。
方法
在这项研究中，我们比较了 38 例伴有微血管疾病的 T2DM 患者和 43 例作为对照的无并发症 T2DM 患者之间 ANCAb 反应的定量差异。
结果
在糖尿病病程方面，复杂组和非复杂组的患者分别具有可比性（9.0 年 vs. 5.0 年；P = 0.065）。研究发现，复杂组中有 27 例（71.1%）对 ANCAb 试验有反应，而非复杂组中有 25 例（58.1%）（P = 0.226；3.53 vs. 2.72ng/mL；P = 0.413）。患有神经病变和心血管并发症的患者对 ANCAb 的反应率为 80.0%，患有神经病变的患者为 76.2%，而对照组为 58.1%（P = 0.398）。单并发症患者对 ANCAb 的反应率为 72.7%，多并发症患者为 68.8%（P = 0.466）。同样，21 例伴有神经病变的 T2DM 患者中有 76.2%（21 例）对 ANCAb 有反应，而对照组中仅有 58.1%（P = 0.158）。
结论
伴有和不伴有并发症的 T2DM 患者之间 ANCAb 的反应没有统计学差异。
Zotero 插件